Rentschler Biopharma SE

In an interview with In Vivo , Rentschler Biopharma CEO Benedikt von Braunmühl discussed the contract drug manufacturing organization’s recent strategic decision to exit the cell and gene therapy man

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

Drug access and supply-chain issues have remained challenging in the aftermath of the COVID-19 pandemic, while increasing research and development in the cell and gene therapy fields are expected to y

An economist by training with a lengthy career in medtech and pharma, Benedikt von Braunmühl is well placed to provide a candid view of the contract development and manufacturing market. He took the h